AYTU Aytu Biopharma, Inc stock chart & analysis
Conviction 40HealthcareScan · Mon, Nov 16, 2026Aytu Biopharma, Inc (AYTU) closed at $1.78 on Nov 16, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 33, RS Rating 22, -41.9% from its 52-week high, -31.5% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
AYTU technical analysis
Trend
AYTU is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 11.6% below the 50-day ($2.01) and 21.8% below the 200-day ($2.28). ADX(14) at 20 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 33, in the bearish half of its range. MACD crossed below its signal line 6 sessions ago. Its RS Rating of 22 puts its weighted 12-month performance ahead of about 22% of the US market.
Volume and volatility
It trades about $49,057 a day on average. ATR(14) is $0.1065, 6.0% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.41) shows distribution.
Key levels
The chart pattern's support is $1.75 and its resistance $2.25. The 52-week range is $1.75 to $3.07; price is 41.9% below the high and 1.7% above the low. The VWAP anchored at the 52-week high is $2.41, above price.
Performance
AYTU returned -2.7% (1 week), -11.4% (1 month), -24.6% (3 months), -18.7% (6 months), -13.6% (1 year), -31.5% (year to date).
About Aytu Biopharma, Inc
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Pharmaceutical Preparations · Listed 2008 · 83 employees
Recent news
- An offer for all AYTU BioPharma (AYTU) common shares is planned but has not yet begun.Stock Titan · Mon, Nov 16, 2026
- Aytu BioPharma, Inc. (AYTU) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance · Mon, Nov 16, 2026
- Aytu BioPharma to be acquired by Rosemont Pharmaceuticals for $2.70 per shareTipRanks · Mon, Nov 16, 2026
- Rosemont to acquire Aytu BioPharma for $2.70 per shareTradingView · Mon, Nov 16, 2026
- Rosemont would buy Aytu BioPharma for $2.70 a share in cash.Stock Titan · Mon, Nov 16, 2026
- Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial ResultsYahoo Finance · Mon, Nov 16, 2026
- Aytu BioPharma (AYTU) Posts $14.8M Revenue, Swings to $3.9M LossTradingView · Mon, Nov 16, 2026
- Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansionYahoo Finance · Mon, Nov 16, 2026
- Rosemont plans to offer $2.70 a share for Aytu within 10 business days.Stock Titan · Mon, Nov 16, 2026
- Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender OfferYahoo Finance · Mon, Nov 16, 2026
SEC filings
EDGAR filings in AYTU · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.